Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes
- 1 March 2015
- journal article
- Published by Elsevier BV in Biomedicine & Pharmacotherapy
- Vol. 70, 33-40
- https://doi.org/10.1016/j.biopha.2014.12.043
Abstract
No abstract availableKeywords
Funding Information
- Commission of the European Community (EU-FP7-REGPOT-2011-1)
This publication has 46 references indexed in Scilit:
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Evidence‐Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 updateInternational Journal of Urology, 2012
- Sunitinib malate for the treatment of renal cell carcinomaExpert Opinion on Pharmacotherapy, 2012
- New Insights into the Biology of Renal Cell CarcinomaHematology/Oncology Clinics of North America, 2011
- EverolimusClinical Cancer Research, 2010
- Kidney CancerJournal of the National Comprehensive Cancer Network, 2009
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive CellsCancer Research, 2009
- Targeted manipulation of apoptosis in cancer treatmentThe Lancet Oncology, 2008
- A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activitiesAnnals Of Oncology, 2007
- The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor CellsNeuroendocrinology, 2007